Skip to main content
. 2022 Jan 17;37(1):30–37. doi: 10.1016/j.virs.2022.01.008

Table 2.

Comparison of the number and frequency (%) of specimens that were positive for subgenomic and genomic E gene with different duration and clinical outcomes.

Days after treatment Subgenomic E
Genomic E
Treatment, n (%)
P Treatment, n (%)
P
Standard Care Lopinavir-Ritonavir Standard Care Lopinavir-Ritonavir
1 14/79
(17.7)
18/68 (26.5) 0.280 74/79 (93.7) 63/68 (92.6) 1a
5 4/29
(13.8)
6/31 (19.4) 0.732a 25/29 (86.2) 27/31 (87.1) 1a
10 0/19
(0)
2/17 (11.8) 0.216a 18/19 (94.7) 13/17 (76.5) 0.167a
14
0/7
(0)
2/17 (11.8)
1a
7/7 (100)
15/17 (88.2)
1a
Outcome Death Recovery P Outcome Death Recovery P





1 18/58
(31)
14/89 (15.7) 0.046 56/58
(96.6)
81/89 (91) 0.316
5 5/20
(25)
5/40 (12.5) 0.278a 19/20
(95)
33/40 (82.5) 0.249
10 0/4
(0)
2/32 (6.3) 1a 4/4
(100)
27/32 (84.4) 1a
14 1/5
(20)
1/19 (5.3) 0.415a 5/5
(100)
17/19 (89.5) 1a
a

Fisher exact test. Chi-square test was used for the remaining variables comparison if not indicated, by chi2_contingency function in the scipy module in python 3.8.